A Replication-Defective Herpes Simplex Virus (HSV)-2 Vaccine, HSV529, is Safe and Well-Tolerated in Adults with or without HSV Infection and Induces Significant HSV-2-Specific Antibody Responses in HSV Seronegative Individuals
Dropulic L, Wang K, Oestreich M, Pietz H, Garabedian D, Jegaskanda S, Dowdell K, Nguyen H, Laing K, Koelle D, Azose A, Hunsberger S, Lumbard K, Chen A, Chang L, Phogat S, Cohen J. A Replication-Defective Herpes Simplex Virus (HSV)-2 Vaccine, HSV529, is Safe and Well-Tolerated in Adults with or without HSV Infection and Induces Significant HSV-2-Specific Antibody Responses in HSV Seronegative Individuals. Open Forum Infectious Diseases 2017, 4: s415-s416. PMCID: PMC5630753, DOI: 10.1093/ofid/ofx163.1041.Peer-Reviewed Original ResearchT cell assaysThird dose of vaccineDose of vaccineAntibody dependent cellular cytotoxicityT cell responsesGroup 3 subjectsSanofi PasteurGroup 1Placebo recipientsThird doseSeronegative individualsVaccine recipientsHSV-2-specific antibody responsesSolicited injection site reactionsCD8 T cell responsesCD4 T cell responsesGroup 3Systemic reactionsADCC-mediating antibodiesPlacebo-controlled trialHSV-2 vaccinesSolicited systemic reactionsInjection site reactionsDependent cellular cytotoxicityCellular immune responses
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply